Právní předpis byl sestaven k datu 19.09.2014.
Zobrazené znění právního předpisu je účinné od 20.12.2013 do 19.09.2014.
98
XXXXXXX
Xxxxxxxxxxxx zahraničních věcí,
xxxxxx xx xxxx x xxxxxxxx xxxxxxx Xxxxxxxxxxxx xxxxxxxxxxxx věcí x. 58/2007 Xx. x. s. x x. 46/2008 Xx. x. s. a xxxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 97/2012 Xx. x. x. x Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx xxxxxxx, že xxx 12. xxxxxxxxx 2012 xxxx xxxxxxxxx ředitelkou XXXXXX xxxxxxxx xxxxxxxxx xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx xxxxx x xxxxx - Mezinárodní xxxxxxxx Mezinárodní úmluvy xxxxx xxxxxxx xx xxxxxx1).
X xxxxx xxxxxx Xxxxxxx X xxxxxxxx souhlas Xxxxxxxxx Xxxxx xxxxxxxxx.
Xxxx xxxxx Xxxxxxx I xxxxxxxxx v platnost x souladu x xxxxxxx 34 odst. 3 Xxxxxx dne 1. xxxxx 2013 x tímto dnem xxxxxxxxx v platnost x xxx Českou xxxxxxxxx. Xxxx xxxxxx xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx platit znění Xxxxxxx I Xxxxxxxxxxx xxxxxx xxxxx dopingu xx xxxxxx xxxxxx xx 1. xxxxx 2012 x xxxxxxxxx xxx č. 97/2012 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx I x xxxx překlad xx xxxxxxx xxxxxx xx vyhlašují xxxxxxxx.
1) Xxxxxxxxxxx xxxxxx proti dopingu xx xxxxxx přijatá xxx 19. října 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.
PŘÍLOHA I
XXXXXX XXXXXXXXXX XXXXX X XXXXX DOPINGU XXX ROK 2013
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. xxxxx 2013
Xxxxx xxxxxx 4.2.2 Světového xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx xxxxx xxxxxxxxxx xx "Xxxxxxxxxx xxxxx" kromě xxxxx xx xxxxxx S1, X2, X4.4, S4.5 x X6(x) x Xxxxxxxxxx xxxxx X1, X2 x M3.
|
LÁTKY X XXXXXX XXXXXXXX XXXXX
(XXX XXXXXXX X XXXX XXXXXX)
|
XXXXXXXX XXXXX
S0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx xxxxxxxx x xxxxxxxxxxxxx xxxxxxx Xxxxxxx x xxxx aktuálně xxxxxxxxx pro humánní xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxxxxx xxxx xx ukončené xxxxxxxxxx, syntetické xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
X1. XXXXXXXXXX XXXXX
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. ANDROGENNÍ XXXXXXXXXX XXXXXXXX (XXX):
(a) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-androst-1-en-3β,17β-diol); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (xxxx-4-xx-3β,17β-xxxx); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); xxxxxxx (17α-xxxxxxx-17β-xxxxxxxxxxxxxx-4-xxx[2,3-x]xxxxxxxx); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-chloro-17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; ethylestrenol (19-xxx-17α-xxxxx-4-xx-17-xx); fluoxymesteron; xxxxxxxxxx; xxxxxxxxx (17β-hydroxy-17α-methyl-5α-androstano[2,3-c]-furazan); gestrinon; 4-xxxxxxxxxxxxxxxxxx (4,17β-dihydroxyandrost-4-en-3-on); xxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxx-1-xx-3-xx); methylnortestosteron (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; metribolon (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); xxxxxxxxx; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); quinbolon; stanozolol; xxxxxxxxx; 1-testosteron (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** AAS, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (androst-5-en-3β,17β-diol), xxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx), dihydrotestosteron, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3ß-hydroxyandrost-5-en-17-one), xxxxxxxxxxx x jejich xxxxxxxxxx x isomery, xxx xx s xxxxxxxx xxxxx xx xx:
| &xxxx;
5α-xxxxxxxxx-3α,17α-xxxx
|
&xxxx;
5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx)
|
| &xxxx;
5α-xxxxxxxxx-3α,17β-xxxx
|
&xxxx; |
| &xxxx;
5α-xxxxxxxxx-3β,17α-xxxx
|
&xxxx;
xxx-xxxxxxxxxxxxxxxxxx
|
| &xxxx;
5α-xxxxxxxxx-3β,17β-xxxx
|
&xxxx;
xxxxxxxxxxxxxx
|
| &xxxx;
xxxxxxx-4-xx-3α,17α-xxxx
|
&xxxx;
3α-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-4-xx-3α,17β-xxxx
|
&xxxx;
3β-xxxxxxx-5αxxxxxxxxx-17-xx
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
7α-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17α-xxxx
|
&xxxx;
7β-xxxxxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3α,17β-xxxX
|
&xxxx;
7-xxxx-XXXX
|
| &xxxx;
xxxxxxx-5-xx-3β,17α-xxxx
|
&xxxx;
19-xxxxxxxxxxxxxx
|
| &xxxx;
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx)
|
&xxxx;
19-xxxxxxxxxxxxxxxxx
|
2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:
Klenbuterol, xxxxxxxxxx modulátory xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, xxxxxxxxxx, ale xx x xxxxxxxx xxxxx xx ně.
|
Pro xxxxx skupiny této xxxxx: * "xxxxxxxx" xx xxxxxxxx k xxxxx, xxxxxx xxxx xxxx normálně xxxxxxx xxxxxxxxxx xxxxxxxxx. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, xxxxxx může xxxx xxxxxxxxxx xxxxxxxxx.
|
X2. XXXXXXXXX HORMONY, XXXXXXX FAKTORY X XXXXXXXX XXXXX
Xxxxxxxxxxx xxxxx a jejich xxxxxxxxxx faktory xxxx xxxxxxxx:
1. Xxxxx xxxxxxxxxxx xxxxxxxxxxx (xxxx. xxxxxxxxxxxx (XXX), darbepoetin (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Xxxxxxxxxxxxxx;
4. Xxxxxxx xxxxxx (XX), fibroblastové xxxxxxx faktory (FGFs), xxxxxxxxxxxx xxxxxxx xxxxxx (XXX), xxxxxxxx podobný xxxxxxx xxxxxx-1 (XXX-1), xxxxxxxxxx růstové xxxxxxx (XXX), růstový xxxxxx xxxxxxxx z krevních xxxxxxxx (XXXX) x xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX), stejně xxxx xxxxxxxxx jiné růstové xxxxxxx ovlivňující xxxxxxx xxxx xxxxxxxxx xxxxxxxx xxxxx, šlach a xxxxxx, xxxxxx zásobení, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx svalových vláken;
x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 agonisté xxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx (xxxx. d- x x-), xxxx xxxxxxxx kromě xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx), xxxxxxxxxxx (xxxxxxxxx 36 xxxxxxxxxx za 24 xxxxx) x salmeterolu xxxxx jsou podány x inhalaci x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx salbutamolu x xxxx x xxxxxxxxxxx xxxxx xxx 1000 xx/xx x xxxxxxxxxx xxxxxxxxxxx x xxxx x koncentraci vyšší xxx 40 xx/xx xxxxxx xxxxxxxxxx xx xxxxxxxxx terapeutické použití, xxx xxxx xxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx sportovec xxxxxxxxx kontrolovanou xxxxxxxxxxxxxxxxx xxxxxx, že xxxxxxxxxx xxxxxxxx byl xxxxxxxx xxxxxxxx terapeutické xxxxxxxxx xxxxx xxxxx xxx xxxx uvedené xxxxxxx.
X4. XXXXXXXXX X XXXXXXXXXXX MODULÁTORY
Zakázané xx xxxxxxxxxxx:
1. Xxxxxxxxxx aromatáz, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (xxxxxxxxxxxxxxxxx), 4-androsten-3,6,17-trion (6-xxx),xxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxxxxx, xxx xx x xxxxxxxx pouze xx xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), zahrnující:
Raloxifen, xxxxxxxxx, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx ně.
3. Xxxxxxx antiestrogenní xxxxx xxxxxxxxxx:
Xxxxxxxxxx, xxxxxxxxxxx, klomifen, ale xx x omezením xxxxx na xx.
4. Látky xxxxxxxxxxxx xxxxxx xxxxxxxxxx včetně xxxxxxxxxx xxxxxxxxxx, xxx xx x omezením xxxxx xx xx.
5. Metabolické modulátory:
x) Xxxxxxxx;
x) Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx proliferátory /Xxxxxxxxxx Xxxxxxxxxxxx Activated Receptor δ (XXXXδ) agonists/ (xxxx. GW 1516) x Xxxxxxxx xxxxxxxxxxxxxxx xxx xxxxxxxxxx XXX x xxxxxxxxxxx x XXXX xxxxx /PPARδ-AMP-activated xxxxxxx xxxxxx (XXXX) xxxx agonists/ (xxxx. XXXXX)
S5. DIURETIKA X OSTATNÍ MASKOVACÍ XXXXX
Xxxxxxxxx xxxxx xxxx zakázané. Zahrnují:
Xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxx. xxxxxxxx, xxxxxxxxxx xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x xxxxxxxxx), xxxxxxxxxx x xxxxx xxxxx x xxxxxxxxx xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxx xxxxxxxxxxxx xxx xxxxx anestézi xxxx xxxxxxxx.
Xxxxxxxxx xxxxxxxx:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxx, xxxxxxxx, xxxxxxxx xxxxxxxxxx, xxxxxxxxx, spironolakton, xxxxxxxx (xxxx. bendroflumethiazid, xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx), triamteren a xxxxx látky s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx drospirenonu, xxxxxxxxx x xxxxxxxxx xxxxxx xxxxxxxxxxx x xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx xxxxxxx (Xxx Xxxxxxx, xxxxxxxx Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx prahovým xxxxxxx (xx. xxxxxxxxxx, salbutamol, xxxxxx, xxxxx, xxxxxxx, xxxxxxxxxxxx x pseudoefedrin) xx xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx je xxxxxxxxxx xxxxxxx specifické Xxxxxxxxxxxx xxxxxxx na xxxx látku xxxxx x xx, která xxx xxxx xxxxxxx xx xxxxxxxxxx xxxx xxxxx xxxxxxxxx látku.
ZAKÁZANÉ XXXXXX
M1. XXXXXXXXXX X XXXX X XXXXXXXX KOMPONENTAMI
Zakázané xx xxxxxxxxxxx:
1. Xxxxxx xxxx znovuzavedení xxxxxxxxx, xxxxxxxxx xxxx xxxxxxxxxxx krve nebo xxxxxxxxx krvinek a xxx xxxxxxxxx xxxxxxxx xxxxxxxxxxx původu xx xxxxxxxxx systému.
2. Xxxxx xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx xxxxxxx, zahrnující xxxxxxxxxxxx xxxxxxxxxxxxx produkty (např.krevní xxxxxxxx xxxxxxxx na xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (XXX13), xxx ne x omezením pouze xx xx. Suplementace xxxxxxxx zakázána není.
3. Jakákoliv xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx nebo x xxxxxxxx komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. CHEMICKÁ A XXXXXXXXX MANIPULACE
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, xx xxxxxx xxxxxxx integritu x platnost Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx xx xxxxxxxx. Xx zahrnuje záměnu x/xxxx úpravu (xxxx. xxxxxxxxxx) xxxx, xxx xx x xxxxxxxx xxxxx xx xx.
2. Xxxxxxxxxx xxxxxx x/xxxx injekce více xxx 50 xx xx 6 xxxxx xxxx xxxxxxxx xxxxx xxxxxx legitimně xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxx xxxxx.
X3. XXXXXX XXXXXX
X xxxxxx xxxxxxxxxx xx xxxxxxx xxxxxxxxxxx xxxxxx xx xxxxxxxx xxxxxxxxxxx:
1. Transfer xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxxx;
2. Použití xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxxxx xxxxx;
| &xxxx;
XXXXX X METODY XXXXXXXX XXX XXXXXXX
|
Xxxxx kategorií S0 xx S5 x X1 až X3 xxxxxxxxx xxxx xxxx Xxx Soutěži xxxxxxxx x xxxxxxxxxxx skupiny:
XXXXXXXX LÁTKY
S6. XXXXXXXXXXX
Všechna stimulancia xxxxxx všech jejich xxxxxxxxxx optických isomerů (xxxx. x- x x-) jsou xxxxxxxx, x výjimkou xxxxxxxx xxxxxxxxx x xxxxxxx xxxxxx xxxxxxxx xxxxxxx x xxxxxxxxxxx xxxxxxxxxx xx Monitorovacího xxxxxxxx xxx rok 2013*.
Xxxxxxxxxxx zahrnují:
(x) Xxxxxxxxxxxx xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, amfetaminil, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxxx, bromantan, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx, fenfluramin, xxxxxxxx, xxxxxxxxxxx, fenproporex, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), furfenorex, xxxxxxxxxxx, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, mefenorex, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxx, p-methylamfetamin, prenylamin, xxxxxxxxx.
Stimulancium, xxxxx xxxx xxxxxxxx uvedeno x tomto xxxxxxxx, xx Specifickou xxxxxx.
(x) Xxxxxxxxxx stimulancia (xxxxxxxx):
Adrenalin**, xxxxx***, xxxxxxx****, xxxxxxxx, etilefrin, xxxxxxxxxxx, xxxxxxxxxxx, fenprometamin, xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxxxx****, methylfenidát, xxxxxxxxxxxxxxx (dimetylpentylamin), niketamid, xxxxxxxxxxx, xxxxxxxxx, oxilofrin, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxxxx, pseudoefedrin*****selegilin, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxx x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Následující xxxxx zahrnuté do Xxxxxxxxxxxxxx xxxxxxxx 2013 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.
** Xxxxxxx xxxxxx xxxxxxxxxx (např. nosní, xxxx aplikace) xxxx xxxx podání společně x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx je xxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx a methylefedrin xxxx xxxxxxxx při xxxxxxxxxxx vyšší xxx 10 xxxxxxxxxx x 1 ml xxxx.
***** Pseudoefedrin xx xxxxxxx, pokud xxxx xxxxxxxxxxx x xxxx xx xxxxx xxx 150 mikrogramů xx xxxxxxxx
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx a jeho xxxxxxxx, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, petidin.
X8. XXXXXXXXXXX
Přírodní (např. xxxxx, konopí x xxxxxxxxx) xxxx syntetický xxxxx9-xxxxxxxxxxxxxxxxxxx (XXX) x xxxxxxxxxxxxxx (xxxx. "Xxxxx" /XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx xxxxxx, xxxxxxxx, nitrožilní xxxx xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
| &xxxx;
LÁTKY ZAKÁZANÉ X XXXXXXXX XXXXXXXX
|
X1. ALKOHOL
Xxxxxxx (xxxxxx) je xxxxxxxx pouze Xxx Xxxxxxx v následujících xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx xxxxxxxx xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) xx 0.10 g/l.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (XXX)
∙ Letecké xxxxxx x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (FITA)
∙ Motocyklový sport (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
P2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx pouze Xxx Xxxxxxx x xxxxxxxxxxxxx sportech.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxx (IGF)
∙ Xxxxxxxxxxx (FITA, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - xxxxx xx xxxxxx a xxxxxxxxxxx xxxxxxxx-xxxxx x X-xxxxx,x snowboard X-xxxxx x "xxx xxx"
∙ Xxxxxxx (ISSF, XXX) (xxxxxxxx xxxx Xxxx xxxxxx)
∙ Xxxxx (WDF)
Xxxx-xxxxxxxxx xxxxxxxx následující xxxxx:
Xxxxxxxxxx, alprenolol, atenolol, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx, metoprolol, xxxxxxx, xxxxxxxxxx, xxxxxxxx, propranolol, xxxxxxx, timolol, xxx xx x omezením xxxxx na ně.
Xxxxxxxxx
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxxxx xxxxxxxxx xxxx 20.12.2013.
Xxxxxx xxxxxxx x. 98/2013 Xx. x. x. xxx xxxxxx xxxxxxx xxxxxxxxx č. 47/2014 Sb. m. s. s xxxxxxxxx xx 20.9.2014.
Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není aktualizováno, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx xxxxxxxx.